Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach
详细信息 查看全文
- 作者：Christian Gissel ; Georg Götz ; Jörg Mahlich ; Holger Repp
- 关键词：Hepatitis C ; Interferon ; free therapy ; Sofosbuvir ; Simeprevir ; Cost ; effectiveness ; Germany ; Efficiency frontier
- 刊名：BMC Infectious Diseases
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：15
- 期：1
- 全文大小：862 KB
- 刊物主题：Infectious Diseases; Parasitology; Medical Microbiology; Tropical Medicine; Internal Medicine;
- 出版者：BioMed Central
- ISSN：1471-2334
文摘
Background The approval of direct-acting antivirals for Interferon-free treatment revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two treatment regimens for genotype 1 infection received conditional approval in the European Union: Sofosbuvir and Ribavirin for 24 weeks and Sofosbuvir and Simeprevir with or without Ribavirin for 12 weeks. We aim to analyze the cost-effectiveness of both regimens in Germany.